SORIATANE

This brand name is authorized in United States. It is also authorized in Canada, France.

Active ingredients

The drug SORIATANE contains one active pharmaceutical ingredient (API):

1	Acitretin UNII LCH760E9T7 - ACITRETIN
	Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate.
	Read more about Acitretin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SORIATANE Capsule	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D05BB02	Acitretin	D Dermatologicals → D05 Antipsoriatics → D05B Antipsoriatics for systemic use → D05BB Retinoids for treatment of psoriasis
Discover more medicines within D05BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02070847, 02070863
FR	Base de données publique des médicaments	60292349, 64225999
US	FDA, National Drug Code	0145-0090, 0145-0091